Defining the challenges and opportunities for using patient‐derived models in prostate cancer research-Reference-Cited by-同舟云学术

Defining the challenges and opportunities for using patient‐derived models in prostate cancer research

Published:2024-03-07 Issue:7 Volume:84 Page:623-635
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Brennen W. Nathaniel¹²³^ORCID,Le Magnen Clémentine⁴⁵⁶^ORCID,Karkampouna Sofia⁷,Anselmino Nicolas⁸,Bock Nathalie⁹¹⁰¹¹,Choo Nicholas¹²,Clark Ashlee K.¹²,Coleman Ilsa M.¹³,Dolgos Robin⁴⁵⁶^ORCID,Ferguson Alison M.¹⁴¹⁵,Goode David L.¹⁶¹⁷,Krutihof‐de Julio Marianna⁷¹⁸¹⁹,Navone Nora M.⁸,Nelson Peter S.¹³²⁰,O'Neill Edward²¹^ORCID,Porter Laura H.¹²,Ranasinghe Weranja¹²²²²³²⁴,Sunada Takuro²⁵,Williams Elizabeth D.⁹²⁶²⁷^ORCID,Butler Lisa M.²⁸²⁹^ORCID,Corey Eva³⁰^ORCID,van Weerden Wytske M.³¹^ORCID,Taylor Renea A.¹⁶¹⁷³²³³³⁴^ORCID,Risbridger Gail P.¹²¹⁶¹⁷³³³⁴^ORCID,Lawrence Mitchell G.¹²¹⁶¹⁷³³³⁴^ORCID

Affiliation:

1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC) Johns Hopkins University Baltimore Maryland USA

2. Department of Urology, James Buchanan Brady Urological Institute Johns Hopkins University Baltimore Maryland USA

3. Department of Pharmacology & Molecular Sciences Johns Hopkins University Baltimore Maryland USA

4. Institute of Medical Genetics and Pathology, University Hospital Basel University of Basel Basel Switzerland

5. Department of Urology University Hospital Basel Basel Switzerland

6. Department of Biomedicine, University Hospital Basel University of Basel Basel Switzerland

7. Urology Research Laboratory, Department for BioMedical Research University of Bern Bern Switzerland

8. Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers The University of Texas MD Anderson Cancer Center Houston Texas USA

9. School of Biomedical Sciences at Translational Research Institute, Faculty of Health Queensland University of Technology (QUT) Brisbane QLD Australia

10. Max Planck Queensland Centre for the Materials Science of Extracellular Matrices Queensland University of Technology (QUT) Brisbane QLD Australia

11. Centre for Biomedical Technologies Queensland University of Technology Brisbane QLD Australia

12. Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute Cancer Program Monash University Clayton VIC Australia

13. Division of Human Biology Fred Hutchinson Cancer Center Seattle Washington USA

14. Department for BioMedical Research University of Bern Bern Switzerland

15. Katharina Gaus Light Microscopy Facility, Mark Wainwright Analytical Centre, Division of Research and Enterprise University of New South Wales Sydney NSW Australia

16. Peter MacCallum Cancer Centre Melbourne VIC Australia

17. Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia

18. Department of Urology Inselspital, Bern University Hospital, University of Bern Bern Switzerland

19. Department for BioMedical Research, Translational Organoid Resource University of Bern Bern Switzerland

20. Division of Clinical Research Fred Hutchinson Cancer Center Seattle Washington USA

21. Nuffield Department of Surgical Sciences University of Oxford Oxford UK

22. Department of Surgery Monash University Melbourne VIC Australia

23. Department of Urology Monash Health Melbourne VIC Australia

24. Department of Urology Austin Health Melbourne VIC Australia

25. Department of Urology Kyoto University Graduate School of Medicine Kyoto Japan

26. Australian Prostate Cancer Research Centre—Queensland Brisbane QLD Australia

27. Centre for Genomics and Personalised Health Queensland University of Technology (QUT) Brisbane QLD Australia

28. South Australian Immunogenomics Cancer Institute University of Adelaide Adelaide SA Australia

29. Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute Adelaide SA Australia

30. Department of Urology University of Washington Seattle Washington USA

31. Department of Urology Erasmus Medical Center Rotterdam The Netherlands

32. Department of Physiology, Biomedicine Discovery Institute Cancer Program Monash University Clayton VIC Australia

33. Cabrini Institute, Cabrini Health Malvern VIC Australia

34. Melbourne Urological Research Alliance, Biomedicine Discovery Institute Monash University Melbourne VIC Australia

Abstract

AbstractBackgroundThere are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes translational prostate cancer research because the range of models does not reflect the diversity of disease seen in clinical practice. In response to this challenge, research laboratories around the world have been developing new patient‐derived models of prostate cancer, including xenografts, organoids, and tumor explants.MethodsIn May 2023, we held a workshop at the Monash University Prato Campus for researchers with expertise in establishing and using a variety of patient‐derived models of prostate cancer. This review summarizes our collective ideas on how patient‐derived models are currently being used, the common challenges, and future opportunities for maximizing their usefulness in prostate cancer research.ResultsAn increasing number of patient‐derived models for prostate cancer are being developed. Despite their individual limitations and varying success rates, these models are valuable resources for exploring new concepts in prostate cancer biology and for preclinical testing of potential treatments. Here we focus on the need for larger collections of models that represent the changing treatment landscape of prostate cancer, robust readouts for preclinical testing, improved in vitro culture conditions, and integration of the tumor microenvironment. Additional priorities include ensuring model reproducibility, standardization, and replication, and streamlining the exchange of models and data sets among research groups.ConclusionsThere are several opportunities to maximize the impact of patient‐derived models on prostate cancer research. We must develop large, diverse and accessible cohorts of models and more sophisticated methods for emulating the intricacy of patient tumors. In this way, we can use the samples that are generously donated by patients to advance the outcomes of patients in the future.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24682

Reference81 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. The current state of preclinical prostate cancer animal models

3. Next-generation characterization of the Cancer Cell Line Encyclopedia

4. The what, when, and why of human prostate cancer xenografts

5. Experimental in vitro, ex vivo and in vivo models in prostate cancer research